The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 01, 2010

Filed:

Aug. 28, 2006
Applicants:

Karl Schoenafinger, Alzenau, DE;

Swen Hoelder, Frankfurt, DE;

David William Will, Kriftel, DE;

Hans Matter, Langenselbold, DE;

Guenter Mueller, Sulzbach, DE;

Martin Bossart, Frankfurt, DE;

Inventors:

Karl Schoenafinger, Alzenau, DE;

Swen Hoelder, Frankfurt, DE;

David William Will, Kriftel, DE;

Hans Matter, Langenselbold, DE;

Guenter Mueller, Sulzbach, DE;

Martin Bossart, Frankfurt, DE;

Assignee:

Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/501 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); A61K 31/5355 (2006.01); A61K 31/553 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them consisting of the structure of formula I: Wherein R1, R2, A, B, D and E are defined herein. These 4-benzimidazol-2-ylpyridazin-3-ones and their derivatives and compositions comprising them are useful in the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase-3 β (GSK-3β) which is believed to cause the neurodegeneration that results in these diseases.


Find Patent Forward Citations

Loading…